A hazard associated with the use of a face mask: case report by Potgieter, S.V. & Mostert, J.W.
21 November 1959 S.A. TYDSKRIF VIR GENEESKU_TDE 989
isolation, the blood specimen should be obtained in the early
stage of illness and during the period of pyrexia, since the
period of viraemia in arthropod-borne virus diseases is
short. If the diagnosis is to be made by serological study,
it is necessary to have paired sera, the first taken as early
as possible in the course of the illness and the second during
the 2nd or 3rd week of convalescence. Both specimens
should be refrigerated without actual freezing and handled
in such manner as to prevent bacterial contamination and
minimize haemolysis.
SUMMARY
I. The isolation of a strain of West Nile virus from the
blood of a naturally infected human being is described.
2. Following infection there was a significant increase in
titre of both neutralizing and haemagglutination-inhibiting
antibodies in tests controlled by the inactivated acute serum
from which the virus was isolated.
3. The isolation of a strain of West ile virus from pooled
tissues (liver and spleen) of a wild-caught crombec warbler
is also described.
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CASE REPORT
J.M.S., a European female patient aged 35 years, underwent
an appendectomy, the anaesthetic time being 1t hours. Pre-
medication consisted of 50 mg. of pethidine, 25 mg. of phenergan,
and 0·65 mg. of atropine. For induction of anaesthesia the
patient received 400 mg. of thiopentone, and anaesthesia was
maintained with halothane vaporized from a RowbOlham bottle
Hazards directly associated with the clinical application of
face masks for purposes of anaesthesia, of resuscitation, or
both, are not generally known. A sequela is here reported,
with a brief discussion of the care needed in the use of rubber
face masks, and the results of an investigation prompted by
our suspicion (which pro.ved to be unfounded) that the
new chemically-active anaesthetic halothane (fiuothane)
might be incriminated.
At the Karl Bremer Hospital it is standard practice for the
anaesthetic face masks to be washed with hexachlorophene
soap and water only after each use and powdered with talc
when dry.
inserted into the inspiratory limb of a semi-closed Boyle mark-I I
circle absorption system. A dose of 60 mg. of gallamine ('flaxedil')
was given fractionally to aid relaxation. Oxygen only, at a flow
rate of 1 litre per minute, was led into the absorption system.
A size 3 M. & LE. 'Everseal' rubber mask (Figs. 1 and 2) was
fixed tightly in position by a harness, over a rubber Water's
oropharyngeal airway, in such a way that the chin was held up
by the mask, so that manual support of the jaw was unnecessary.
On the following morning a chemical burn exhibiting some dark
pigmentation (Fig. 3) withstood the attempts of one of the nurses
to remove it; the lesion resembled an impression of the face mask
so closely that the nurse tried to rub it 011' believing it to be a
stain.
DISCUSSION
While it is obvious that the eyes need protection from a mask,
neither of us had seen or heard of such a burn on the face.
Trivial lacerations of the lips are known to result from im-
properly applied masks, but there was nothing to suggest
significant pressure or allergy in the present case. Dr. J.
Marshal!, consultant dermatologist at the hospital, confinned
the diagnosis of primary chemical bum followed by increased
pigmentation which in time would disappear entirely. The
lesion faded and was, in fact, hardly visible 14 days later.ow of King Edward VIII Hospital, Durban.*
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Our investigation was therefore directed to the anaesthetic
masks as such. Something must have rendered the mask
used in this case harmful to the skin. On smelling the masks
one with a slight but distinct phenolic odour was found.
On questioning, the anaesthetic nurse stated that, after
cleaning a theatre in which a patient suffering from tetanus
had been operated on, the anaesthetic equipment had been
left to soak in a weak solution of 'instrument detto!' and
water. After this the mask had been washed with soap
and water, and because it still had a faint smell it was again
washed with soap and water, and only then made available
for routine use. To exclude a possible sensitivity in the
patient a patch test was done on her with antistatic rubber
soaked in (1) halothane, (2) a 5 % solution of 'instrument
dettol', and (3) halothane and a 5% solution of 'instrument
detto!'; and with white lint soaked in (1) 5 % 'instrument
dettol' and (2) halothane. The patches were covered with
.waterproof adhesive plaster and left for 48 hours. Upon
removal, and after washing the skin to remove traces of the
black antistatic rubber, no skin lesion could be seen.
CONCLUSION
A patient suffered a primary chemical burn of the face after
a surgical procedure, as a result of 'instrument dettol' being
in contact with the face mask used (a practice warned
against by the manufacturers). Although it was a weak
solution repeated subsequent washing with soap and water
did not remove it. A first-degree burn was sustained by the
first patient on whom it was subsequently used.
We wish to thank Dr. R. S. Cormack, Medical Superintendent
(acting), Karl Bremer Hospital, for permission to publish this
case report.
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In recent years progress in the management and treatment of
mental illness has been accelerated by several new pharmaco-
logical substances; notably the phrenotropic substances such as
cWorpromazine, phenothiazine derivatives, and the rauwolfia
alkaloids. These drugs have been used to treat, more successfully
than before, patients suffering from mania, agitation, patho-
logical excitement, states of elation, and morbid anxiety, especi-
ally the emotionally and mentally disturbed patients who have
been unresponsive to psychotherapy and the prevailing methods
of sedation and physical treatments, such as insulin coma therapy
and electric convulsive therapy (ECT). .
Until recently, the drugs used for the treatment of depres-
sive states have been excitatory substances (stimulants) such as
the amphetamines, pipadrol (meratran), and methyl phenyl-
(a-piperidyl) acetate hydrocWoride (ritalin), all of which have a
similar psychopharmacological action. Their effect has been
so limited and temporary as to be considered only of adjuvant
assistance in the management and treatment of depressive states.
For the past 20 years, ECT has proved to be the most rapid
and effective form of treatment for depressive states, notably
those of endogenous nature.
A turning point seems to have been reached with the advent
of the potent new antidepressant drugs which are at present on
clinical trial; they open up a new field in the therapy and approach
to the management of patients with depressive states.
Some striking results in alleviating depressive phenomena have
been achieved in the past few years following the development
of Tofranil by J. R. Geigy S.A., Basle (synthesized by Haefliger).
Tofranil is an iminodibenzyl derivative with the same side-chain
as cWorpromazine but with a different ring system. Chemically,
the drug is N-(3 dimethylarninopropyl) iminodibenzyl hydro-
chloride. Biochemical studies have shown that Tofranil is not a
stimulant of the central nervous system, neither has it a pro-
nounced hypnotic-sedative action. Animal experiments show
demonstrable anti-serotonin and anti-cholinergic properties and
some adrenergic action. It does not inhibit amino-oxidase. The
exact mode of action is as yet not known. Tofranil has been
reliably reported clinically to effect a specific anti-depressive action
on pathological depressive states, producing gradual lessening and
frequently a disappearance of the symptoms and signs of de-
pressive states. Improvement, when it occurs, is manifested
usually within 2-6 weeks after the commencement of therapy.
From clinical observations it appears that Tofranil has a mild
sedative action. It does not interfere with sleep. It facilitates
verbal flow and increases mental alertness and useful activity
and a sense of well-being, especially in endogenous depressive
. states. Its effect on the cardiovascular system, by causing ortho-
static hypotension, may limit its use in certain cases. Serious
liver damage, blood dyscrasias or toxic effe~ts on the kidneys
or the central nervous system have not yet been reported after
a 3-year trial.
-SELECITON AND SUBJECTS
The present limited study and preliminary evaluation of the
results of treatment is based on the observation of 30 patients
from private practice to whom Tofranil had been given over a
,6-month trial period. The patients were told that the drug was
experimental and informed of the possible side-effects. These
patients received no formal psychotherapy and they were treated
on an out-patient basis. Their life situation remained virtually
unchanged during the treatment period, thus excluding the possible
favourable psychotherapeutic influences of the hospital millieu;
and the therapeutic situation approximates to one which is likely
to exist when selected cases of endogenous depression, preferably
confirmed by a psychiatrist as suitable for treatment with the
drug, receive this form of therapy from their general practitioner
when the drug becomes available in the near future.
DIAGNOSTIC CATEGORIES
The clinical diagnostic categories comprised 3 main groups:
Group 1: Primary depressive states (predominantly endogenous)
of a chronic recurring nature. These patients suffered from re-
current, typical, primary endogenous depressive states as de-
scribed below; I have known them well over a period of years,
and they constitute a specially selected group. All had received
previous courses of ECT and other available forms of ttJ,erapy
with unsustained benefit, necessitating monthly maintenance
ECT. Complete relief of their depressive states had not lasted
longer than 3--4 weeks at a time without montWy ECT since the
onset of the last severe attack (12-18 months before the institu-
tion of maintenapce ECT).
Group 2: Primary depressive states (predominantly endogenous)
of recent onset (3-6 months duration), typical and atypical (dis-
guised depressive equivalents). This group of 12 cases was com-
prised of moderately severe and severe cases (deeply depressed
with suicidal prepccupation). Of these cases 5 were subject to
typical endogenous depression (described below}-2 had suffered
from similar previous depressive illness, 3 to atypical depression
(disguised endogenous depressive equivalents), 2 to endogenous
depressive states (manic-depressive psychosis), and 2 to endo-
genous depression (involutional). All these would have received
ECT if Tofranil had not been available, and 10 cases referred for
psychiatric treatment were seen for the first time suffering from a
first severe attack of depression.
Group 3: Secondary depressive states (predominantly neurotic).
These cases were a mixed group in which the predominant com-
plaint of depression, in varying degrees of severity, occurred in
